Evoke Pharma Stock News

Lantern Pharma (NASDAQ:LTRN) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership. Earnings & Valuation This table compares Lantern Pharma and Evoke Pharma’s top-line revenue, earnings per […]

Evoke Pharma, Inc. (NASDAQ:EVOK)s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.24 and traded as low as $0.90. Evoke Pharma shares last traded at $0.92, with a volume of 251,407 shares. The company has a quick ratio of 8.18, a current []

Evoke Pharma's (EVOK) CEO Dave Gonyer on Q3 2021 Results - Earnings Call Transcript

SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, to

Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis

The online pet retailer developed a cult following for its fast shipping and automatic deliveries of food and supplies.

The shares of Evoke Pharma, Inc. (NASDAQ: EVOK) increased by over 10% pre-market. This is why it happened.

Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 ce

The shares of Evoke Pharma, Inc. (NASDAQ: EVOK) fell by over 12% pre-market. This is why it happened.

Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2021 Results - Earnings Call Transcript

Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ®

Participating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk

Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers

Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk Extends commitmen

Results demonstrate continued increased awareness and intent to prescribe GIMOTI Results demonstrate continued increased awareness and intent to prescribe GIMOTI